Alnis BioSciences, Inc.

Location:NC, US
Speaker:Stephen Barry
Primary Industry:Pharma & Biotech
Executive Summary:The convergence of diagnostic and therapeutic methods is leading to a new age of personalized medicine. Nowhere is this more important than in the treatment of cancer, a class of diseases characterized by uncontrolled growth of abnormal, genetically-mutated cells. Molecular diagnostic advances are providing valuable information on specific defects and potential targets found in tumor tissues, and the identification of cancer signatures that characterize an individual’s disease will continue to improve. This is important because current cell-killing treatments such as radiation and chemotherapy can not be sufficiently directed to tumors, and severe-side effects require treatment to be stopped before the patient is cured. Improved treatments are emerging- examples include monoclonal antibody therapies and nanoparticle delivery- and are based upon the targeting or exploitation of the distinguishing molecular and structural signatures of tumors. Alnis BioSciences is going beyond first generation targeting through the creation of MagNaGel™ nanoparticles that can be tracked in the body using MRI equipment already in place in hospitals to confirm tumor-localization, and that can then be selectively activated within tumors to eradicate cancer cells. MagNaGel nanoparticles combine diagnostic, drug and device capabilities to better detect, diagnose and treat cancer.
Venture is:A-Round


Corporate Presentations:

  • Air Products
  • BASF
  • Eastman Kodak Company
  • Genzyme
  • Goodrich
  • Hewlett-Packard
  • Honda
  • Medtronic
  • Merck
  • Sanyo

Reserved Presentations:

  • ExxonMobil
  • IBM

Partnering Events:
(full access included)

Platinum Sponsor

University of Hawaii

Press Sponsor

Business Wire

Commercialization Partner



Invest Australia AzTE Technology Enterprises

Media Sponsors

(joint with Nanotech 2007) Nature
Red Herring

Supporting Organizations

Boston University
Midwest Research University Network


“A major challenge for both the technology and the financial communities is finding a forum in which all parties can interact and explore possibilities for future innovation. TechConnect was created to fill this void, bringing both sides together under one roof into a setting that ultimately will help significant ground-breaking concepts come to life.”
Matthew Laudon, Co-Founder and Director of TechConnect